Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after surgery. It enrolled 709 patients, assessing disease-free survival and overall survival as primary end points.

EP: 1.MIUC: Risk of Recurrence After Radical Cystectomy

EP: 2.High-Risk MIBC: Adjuvant Therapy Options After Radical Cystectomy

Now Viewing

EP: 3.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Aims and Design

EP: 4.Phase 3 CheckMate 274 Study: Adjuvant Nivolumab for High-Risk MIUC—Updated Results

EP: 5.Dr. Galsky’s Perspectives on the CheckMate 274 Data Results

EP: 6.Adjuvant Anti–PD-1 Decision-Making: PD-L1 Expression, Residual Disease, and Variant Histologies

EP: 7.Current and Emerging Uses of ctDNA in the Adjuvant MIUC Setting

EP: 8.Adjuvant ICI for High-Risk MIUC: AE Monitoring and Management

EP: 9.Adjuvant ICI for High-Risk MIUC: Patient Counseling

EP: 10.Dr. Galsky’s Perspectives on Subcutaneous ICI Dosing

Video content above is prompted by the following:

• Please provide an overview of the CheckMate 274 clinical trial (eg, design and population enrolled).

Recent Videos